Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

HIV Infection

Free Subscription 29.10.2018 2 AIDS Res Hum Retroviruses 2 Antivir Ther 1 BMJ 1 Cancer 2 Clin Infect Dis 1 Drugs 3 HIV Med 8 J Acquir Immune Defic Syndr 1 J Infect Dis 7 J Virol 1 Lancet 1 Lancet Haematol 2 Lancet HIV 2 Lancet Infect Dis 1 MMWR Morb Mortal Wkly Rep 1 Neurology 1 Pediatr Infect Dis J 1 Pediatrics 1 PLoS Med 21 PLoS One 1 PLoS Pathog 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

AIDS Res Hum Retroviruses

1. LEVY ME, Greenberg AE, Magnus M, Younes N, et al
   Immunosuppression and HIV Viremia Associated with More Atherogenic Lipid Profile in Older People with HIV.
   AIDS Res Hum Retroviruses. 2018 Oct 24. doi: 10.1089/AID.2018.0145.
   PubMed     Text format     Abstract available
   
   
2. JEAN MJ, Fiches G, Hayashi T, Zhu J, et al
   Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors.
   AIDS Res Hum Retroviruses. 2018 Oct 23. doi: 10.1089/AID.2018.0153.
   PubMed     Text format     Abstract available
   
   

   
   Antivir Ther

3. DENAULT JS, Cabot JF, Langlois H, Marcotte S, et al
   Optimizing concentrations of concomitant antiretrovirals by reducing etravirine doses: two case reports of complex drug-drug interactions.
   Antivir Ther. 2018 Oct 24. doi: 10.3851/IMP3274.
   PubMed     Text format     Abstract available
   
   
4. FERRARI D, Spagnuolo V, Manca M, Bigoloni A, et al
   Increased dose of dolutegravir as a potential rescue therapy in multi-experienced patients.
   Antivir Ther. 2018 Oct 24. doi: 10.3851/IMP3275.
   PubMed     Text format     Abstract available
   
   

   
   BMJ

5. TORJESEN I
   HIV diagnoses fall by a quarter after PrEP roll-out in Australia.
   BMJ. 2018;363:k4382.
   PubMed     Text format    
   
   

   
   Cancer

6. ORTIZ AP, Engels EA, Nogueras-Gonzalez GM, Colon-Lopez V, et al
   Disparities in human papillomavirus-related cancer incidence and survival among human immunodeficiency virus-infected hispanics living in the United States.
   Cancer. 2018 Oct 22. doi: 10.1002/cncr.31702.
   PubMed     Text format     Abstract available
   
   

   
   Clin Infect Dis

7. MEIRING S, Cohen C, de Gouveia L, du Plessis M, et al
   Declining incidence of invasive meningococcal disease in South Africa: 2003-2016.
   Clin Infect Dis. 2018 Oct 23. pii: 5142640. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   
8. RIDDLER SA, Balkus JE, Parikh UM, Mellors JW, et al
   Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the MTN-020/ASPIRE Phase III Trial of the Dapivirine Vaginal Ring.
   Clin Infect Dis. 2018 Oct 22. pii: 5140190. doi: 10.1093.
   PubMed     Text format     Abstract available
   
   

   
   Drugs

9. DEEKS ED
   Doravirine: First Global Approval.
   Drugs. 2018;78:1643-1650.
   PubMed     Text format     Abstract available
   
   

   
   HIV Med

10. 
    A note of thanks to referees for Volume 19, 2018.
    HIV Med. 2018;19:756-758.
    PubMed     Text format    
    
    
11. BALASKO A, Keynan Y
    Shedding light on IRIS: from Pathophysiology to Treatment of Cryptococcal Meningitis and Immune Reconstitution Inflammatory Syndrome in HIV-Infected Individuals.
    HIV Med. 2018 Oct 25. doi: 10.1111/hiv.12676.
    PubMed     Text format     Abstract available
    
    
12. LIEGEOIS F, Eymard-Duvernay S, Boyer S, Maradan G, et al
    Heterogeneity of virological suppression in the national antiretroviral programme of Cameroon (ANRS 12288 EVOLCAM).
    HIV Med. 2018 Oct 25. doi: 10.1111/hiv.12681.
    PubMed     Text format     Abstract available
    
    

    
    J Acquir Immune Defic Syndr

13. MWINNYAA G, Gray RH, Grabowski MK, Ssekasanvu J, et al
    Brief Report: Age-Disparate Relationships and HIV Prevalence Among Never Married Women in Rakai, Uganda.
    J Acquir Immune Defic Syndr. 2018;79:430-434.
    PubMed     Text format     Abstract available
    
    
14. MOORHOUSE M, Maartens G, Francois Venter WD, Moosa MY, et al
    Third-line antiretroviral therapy programme in the South African public sector: cohort description and virological outcomes.
    J Acquir Immune Defic Syndr. 2018 Oct 10. doi: 10.1097/QAI.0000000000001883.
    PubMed     Text format     Abstract available
    
    
15. MILAM J, Jain S, Dube MP, Daar ES, et al
    Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study among Individuals at Risk for HIV.
    J Acquir Immune Defic Syndr. 2018 Oct 10. doi: 10.1097/QAI.0000000000001885.
    PubMed     Text format     Abstract available
    
    
16. STREED CG JR, Goldstein Z, Poteat T, Mukherjee M, et al
    Response to: Cardiovascular Risk Profile of Transgender Women with HIV.
    J Acquir Immune Defic Syndr. 2018 Oct 10. doi: 10.1097/QAI.0000000000001884.
    PubMed     Text format    
    
    
17. MONTOYA JL, Campbell LM, Paolillo EW, Ellis RJ, et al
    Inflammation Relates to Poorer Complex Motor Performance among Adults Living with HIV on Suppressive Antiretroviral Therapy.
    J Acquir Immune Defic Syndr. 2018 Oct 25. doi: 10.1097/QAI.0000000000001881.
    PubMed     Text format     Abstract available
    
    
18. MUSTANSKI B, Morgan E, D'Aquila R, Birkett M, et al
    Individual and Network Factors Associated with Racial Disparities in HIV Among Young Men who have sex with Men: Results from the Radar Cohort Study.
    J Acquir Immune Defic Syndr. 2018 Oct 25. doi: 10.1097/QAI.0000000000001886.
    PubMed     Text format     Abstract available
    
    
19. 
    HIV-1 Proviral Sequence and Treatment Outcome of Virologically Suppressed Patients Switching to Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate: Erratum.
    J Acquir Immune Defic Syndr. 2018;79:e111.
    PubMed     Text format    
    
    
20. AMMASSARI A, Stohr W, Antinori A, Molina JM, et al
    Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial.
    J Acquir Immune Defic Syndr. 2018;79:481-490.
    PubMed     Text format     Abstract available
    
    

    
    J Infect Dis

21. LAROUCHE A, Milton McSween KA, Calderon V, Fauteux-Daniel S, et al
    Quasispecies Diversity Is a Major Risk Factor for Vertical Hepatitis C Virus Transmission.
    J Infect Dis. 2018 Oct 25. pii: 5144832. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    J Virol

22. YI DR, An N, Liu ZL, Xu FW, et al
    Human MxB inhibits the replication of HCV.
    J Virol. 2018 Oct 17. pii: JVI.01285-18. doi: 10.1128/JVI.01285.
    PubMed     Text format     Abstract available
    
    
23. JAMES KL, de Silva T, Brown K, Whittle H, et al
    LOW-BIAS RNA SEQUENCING OF THE HIV-2 GENOME FROM BLOOD PLASMA.
    J Virol. 2018 Oct 17. pii: JVI.00677-18. doi: 10.1128/JVI.00677.
    PubMed     Text format     Abstract available
    
    
24. MURAKOSHI H, Kuse N, Akahoshi T, Yu Z, et al
    Broad recognition of circulating HIV-1 by HIV-1-specific CTLs with strong ability to suppress HIV-1 replication.
    J Virol. 2018 Oct 17. pii: JVI.01480-18. doi: 10.1128/JVI.01480.
    PubMed     Text format     Abstract available
    
    
25. LO M, Zhu J, Hansen SG, Carroll T, et al
    Acute infection and subsequent subclinical reactivation of herpes simplex virus-2 after vaginal inoculation of rhesus macaques.
    J Virol. 2018 Oct 17. pii: JVI.01574-18. doi: 10.1128/JVI.01574.
    PubMed     Text format     Abstract available
    
    
26. CAI Y, Abdel-Mohsen M, Tomescu C, Xue F, et al
    BCL6 Inhibitor-mediated Downregulation of pSAMHD1 and T Cell Activation Are Associated with Decreased HIV Infection and Reactivation.
    J Virol. 2018 Oct 24. pii: JVI.01073-18. doi: 10.1128/JVI.01073.
    PubMed     Text format     Abstract available
    
    
27. APPOURCHAUX R, Delpeuch M, Zhong L, Burlaud-Gaillard J, et al
    Functional mapping of regions involved in the negative imprinting of virion particles infectivity and in target cell protection by the Interferon-Induced Transmembrane Protein 3 (IFITM3) against HIV-1.
    J Virol. 2018 Oct 24. pii: JVI.01716-18. doi: 10.1128/JVI.01716.
    PubMed     Text format     Abstract available
    
    
28. LI S, Ahmad I, Shi J, Wang B, et al
    Murine leukemia virus glycosylated Gag reduces murine SERINC5 protein expression at steady-state levels via endosome/lysosome pathway to counteract the SERINC5 antiretroviral activity.
    J Virol. 2018 Oct 24. pii: JVI.01651-18. doi: 10.1128/JVI.01651.
    PubMed     Text format     Abstract available
    
    

    
    Lancet

29. FOREMAN KJ, Marquez N, Dolgert A, Fukutaki K, et al
    Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories.
    Lancet. 2018 Oct 16. pii: S0140-6736(18)31694.
    PubMed     Text format     Abstract available
    
    

    
    Lancet Haematol

30. PAPANICOLAOU G
    Predictive value of faecal adenoviral load for viraemia.
    Lancet Haematol. 2018;5:e385-e386.
    PubMed     Text format    
    
    

    
    Lancet HIV

31. GRULICH AE, Guy R, Amin J, Jin F, et al
    Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.
    Lancet HIV. 2018 Oct 17. pii: S2352-3018(18)30215.
    PubMed     Text format     Abstract available
    
    
32. MCCORMACK S
    What happens when PrEP is scaled up? Results from EPIC-NSW.
    Lancet HIV. 2018 Oct 16. pii: S2352-3018(18)30253.
    PubMed     Text format    
    
    

    
    Lancet Infect Dis

33. LOYSE A, Burry J, Cohn J, Ford N, et al
    Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries.
    Lancet Infect Dis. 2018 Oct 18. pii: S1473-3099(18)30493.
    PubMed     Text format     Abstract available
    
    
34. VARIAVA E, Martinson N
    Occult rifampicin-resistant tuberculosis: better assays are needed.
    Lancet Infect Dis. 2018 Oct 17. pii: S1473-3099(18)30550.
    PubMed     Text format    
    
    

    
    MMWR Morb Mortal Wkly Rep

35. HUANG YA, Zhu W, Smith DK, Harris N, et al
    HIV Preexposure Prophylaxis, by Race and Ethnicity - United States, 2014-2016.
    MMWR Morb Mortal Wkly Rep. 2018;67:1147-1150.
    PubMed     Text format     Abstract available
    
    

    
    Neurology

36. LEW BJ, McDermott TJ, Wiesman AI, O'Neill J, et al
    Neural dynamics of selective attention deficits in HIV-associated neurocognitive disorder.
    Neurology. 2018 Oct 17. pii: WNL.0000000000006504.
    PubMed     Text format     Abstract available
    
    

    
    Pediatr Infect Dis J

37. PALMA P, Cotugno N, Rossi P, Giaquinto C, et al
    The Mission is Remission: Hope for Controlling HIV Virus Replication Without ART in Early Treated Perinatally HIV Infected Children.
    Pediatr Infect Dis J. 2018 Oct 19. doi: 10.1097/INF.0000000000002203.
    PubMed     Text format    
    
    

    
    Pediatrics

38. LYON ME, Garvie PA, D'Angelo LJ, Dallas RH, et al
    Advance Care Planning and HIV Symptoms in Adolescence.
    Pediatrics. 2018 Oct 19. pii: peds.2017-3869. doi: 10.1542/peds.2017-3869.
    PubMed     Text format     Abstract available
    
    

    
    PLoS Med

39. GHYS PD, Williams BG, Over M, Hallett TB, et al
    Epidemiological metrics and benchmarks for a transition in the HIV epidemic.
    PLoS Med. 2018;15:e1002678.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

40. MILANES-GUISADO Y, Gutierrez-Valencia A, Trujillo-Rodriguez M, Espinosa N, et al
    Absolute CD4+ T cell count overstate immune recovery assessed by CD4+/CD8+ ratio in HIV-infected patients on treatment.
    PLoS One. 2018;13:e0205777.
    PubMed     Text format     Abstract available
    
    
41. INIESTA C, Alvarez-Del Arco D, Garcia-Sousa LM, Alejos B, et al
    Awareness, knowledge, use, willingness to use and need of Pre-Exposure Prophylaxis (PrEP) during World Gay Pride 2017.
    PLoS One. 2018;13:e0204738.
    PubMed     Text format     Abstract available
    
    
42. KINOSHITA M, Oka S
    Migrant patients living with HIV/AIDS in Japan: Review of factors associated with high dropout rate in a leading medical institution in Japan.
    PLoS One. 2018;13:e0205184.
    PubMed     Text format     Abstract available
    
    
43. BULLA I, Spickanll IH, Gromov D, Romero-Severson EO, et al
    Sensitivity of joint contagiousness and susceptibility-based dynamic optimal control strategies for HIV prevention.
    PLoS One. 2018;13:e0204741.
    PubMed     Text format     Abstract available
    
    
44. MATHEW E, Zhu H, Connelly SM, Sullivan MA, et al
    Display of the HIV envelope protein at the yeast cell surface for immunogen development.
    PLoS One. 2018;13:e0205756.
    PubMed     Text format     Abstract available
    
    
45. NYIRENDA D, Gooding K, Lora W, Kumwenda M, et al
    Complexities and dilemmas in community consultation on the design of a research project logo in Malawi.
    PLoS One. 2018;13:e0205737.
    PubMed     Text format     Abstract available
    
    
46. EJETA E, Beyene G, Balay G, Bonsa Z, et al
    Factors associated with unsuccessful treatment outcome in tuberculosis patients among refugees and their surrounding communities in Gambella Regional State, Ethiopia.
    PLoS One. 2018;13:e0205468.
    PubMed     Text format     Abstract available
    
    
47. JIANG Z, Xiu C, Yang J, Zhang X, et al
    HIV test uptake and related factors amongst heterosexual drug users in Shandong province, China.
    PLoS One. 2018;13:e0204489.
    PubMed     Text format     Abstract available
    
    
48. ZABLOTSKA IB, Gray R, Whittaker B, Holt M, et al
    The estimated number of potential PrEP users among gay-identifying men who have sex with men in Australia.
    PLoS One. 2018;13:e0204138.
    PubMed     Text format     Abstract available
    
    
49. MORALES-RAMIREZ J, Bogner JR, Molina JM, Lombaard J, et al
    Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial.
    PLoS One. 2018;13:e0205368.
    PubMed     Text format     Abstract available
    
    
50. MORAGAS M, Distefano M, Mecikovsky D, Arazi Caillaud S, et al
    Impact of the time to achieve viral control on the dynamics of circulating HIV-1 reservoir in vertically infected children with long-term sustained virological suppression: A longitudinal study.
    PLoS One. 2018;13:e0205579.
    PubMed     Text format     Abstract available
    
    
51. UMEOKONKWO CD, Aniebue PN, Onoka CA, Agu AP, et al
    Patients' satisfaction with HIV and AIDS care in Anambra State, Nigeria.
    PLoS One. 2018;13:e0206499.
    PubMed     Text format     Abstract available
    
    
52. MULUYE AB, Kebamo S, Teklie T, Alemkere G, et al
    Poor treatment outcomes and its determinants among tuberculosis patients in selected health facilities in East Wollega, Western Ethiopia.
    PLoS One. 2018;13:e0206227.
    PubMed     Text format     Abstract available
    
    
53. CHOI JS, Lee SH, Leem AY, Song JH, et al
    Pneumocystis jirovecii pneumonia (PCP) PCR-negative conversion predicts prognosis of HIV-negative patients with PCP and acute respiratory failure.
    PLoS One. 2018;13:e0206231.
    PubMed     Text format     Abstract available
    
    
54. YANG E, Gardner MR, Zhou AS, Farzan M, et al
    HIV-1 inhibitory properties of eCD4-Igmim2 determined using an Env-mediated membrane fusion assay.
    PLoS One. 2018;13:e0206365.
    PubMed     Text format     Abstract available
    
    
55. VALERIAN DM, Mauka WI, Kajeguka DC, Mgabo M, et al
    Prevalence and causes of blood donor deferrals among clients presenting for blood donation in northern Tanzania.
    PLoS One. 2018;13:e0206487.
    PubMed     Text format     Abstract available
    
    
56. JAROLIMOVA J, Kabakyenga J, Bennett K, Muyindike W, et al
    Contraceptive use following unintended pregnancy among Ugandan women living with HIV.
    PLoS One. 2018;13:e0206325.
    PubMed     Text format     Abstract available
    
    
57. KIMARO L, Adinan J, Damian DJ, Njau B, et al
    Prevalence of occupational injuries and knowledge of availability and utilization of post exposure prophylaxis among health care workers in Singida District Council, Singida Region, Tanzania.
    PLoS One. 2018;13:e0201695.
    PubMed     Text format     Abstract available
    
    
58. MOYO S, Gaseitsiwe S, Mohammed T, Pretorius Holme M, et al
    Cross-sectional estimates revealed high HIV incidence in Botswana rural communities in the era of successful ART scale-up in 2013-2015.
    PLoS One. 2018;13:e0204840.
    PubMed     Text format     Abstract available
    
    
59. MATENGE TG, Mash B
    Barriers to accessing cervical cancer screening among HIV positive women in Kgatleng district, Botswana: A qualitative study.
    PLoS One. 2018;13:e0205425.
    PubMed     Text format     Abstract available
    
    
60. FARR K, Ravindran R, Strnad L, Chang E, et al
    Diagnostic performance of blood inflammatory markers for tuberculosis screening in people living with HIV.
    PLoS One. 2018;13:e0206119.
    PubMed     Text format     Abstract available
    
    

    
    PLoS Pathog

61. NAGHAVI MH
    "APP"reciating the complexity of HIV-induced neurodegenerative diseases.
    PLoS Pathog. 2018;14:e1007309.
    PubMed     Text format    
    
    

    
    Proc Natl Acad Sci U S A

62. QUINN CM, Wang M, Fritz MP, Runge B, et al
    Dynamic regulation of HIV-1 capsid interaction with the restriction factor TRIM5alpha identified by magic-angle spinning NMR and molecular dynamics simulations.
    Proc Natl Acad Sci U S A. 2018 Oct 17. pii: 1800796115.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: